Skip to main content

Table 2 Comparison of clinical outcomes between DCB-based treatment and DES-only treatment according to the presence of DM at 2 years follow-up

From: Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease

 

DM (n = 219)

 

Non-DM (n = 289)

DCB-based

treatment

DES-only

treatment

HR

(95% CI)

p Value*

 

DCB-based

treatment

DES-only

treatment

HR

(95% CI)

p Value*

(n = 104)

(n = 115)

 

(n = 150)

(n = 139)

MACE

3 (2.9)

16 (13.9)

0.19 (0.05–0.68)

0.003

 

7 (4.7)

12 (8.6)

0.52 (0.20–1.38)

0.167

Cardiac death

0

4 (3.5)

-

0.044

 

1 (0.7)

2 (1.4)

0.43 (0.03–5.34)

0.481

Myocardial infarction

0

1 (0.9)

-

0.290

 

0

2 (1.4)

-

0.155

Stroke

0

1 (0.9)

-

0.333

 

0

0

-

-

Stent or target lesion thrombosis

0

0

-

-

 

0

1 (0.7)

-

0.316

Target vessel revascularization

2 (1.9)

8 (7.0)

0.27 (0.05–1.34)

0.077

 

6 (4.0)

8 (5.8)

0.69 (0.23–2.07)

0.492

Major bleeding

1 (1.0)

4 (3.5)

0.26 (0.03–2.34)

0.196

 

0

3 (2.2)

-

0.063

  1. Values are presented as n (%). p value* was obtained from the log-rank test
  2. MACE was composed of cardiac death, myocardial infarction, stroke, stent or target lesion thrombosis, target vessel revascularization, and major bleeding (Bleeding Academic Research Consortium bleeding type 3 or greater)
  3. DM = diabetes mellitus; DCB = drug-coated balloon; DES = drug-eluting stent; MACE = major adverse cardiovascular events